Tiziana Life Sciences Ltd
TLSA · XNASCIK 1723069fmd_153N6859HHZVDET0N6MBZGXXYRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Dec 31, 2025, 10 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
| Research and development | 4 | 6 | 6 | 4 | 6 | 13 | 13 | 8 | 5 |
| Operating income | (10) | (10) | (10) | (10) | (28) | (27) | (15) | (18) | (16) |
| Interest expense | 0 | 0 | 0 | 0 | – | – | 1 | 0 | 2 |
| Income before taxes | (10) | (11) | (10) | (10) | (28) | (27) | (15) | (17) | (17) |
| Income tax expense | (0) | (2) | (2) | (2) | (2) | (3) | – | 0 | (5) |
| Net income from continuing operations | (10) | (9) | (8) | (8) | (26) | (23) | – | (18) | (12) |
| Net income | (10) | (9) | (8) | (9) | (26) | (23) | (15) | (18) | (12) |
| Net income to common shareholders | (11) | (9) | 8 | 9 | 26 | 23 | – | – | – |